The global Anti-Infective Agents Market size is expected to reach over USD 144.8 billion by 2026 according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.4% during the forecast period. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.
Organizations, such as the World Health Organization
(WHO) and Centers for Disease control and Prevention (CDC) are actively
involved in spreading awareness amongstpeople regarding the fatal implications
of infectious diseases and the importance of early treatment. The CDC has
collaborated with the National Health Ministry (NHM) in an attempt to spread
awareness and to enhance the treatment of communicable diseases in developing
countries such as Brazil, China, Nigeria, and India.
However, introduction of novel therapeutics
with increased potency and efficacy and the commercialization of pipeline
products, such as commercialization of Omadacycline in 2018 for the treatment
of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the
growth of the anti-infective agents market.
Request a sample copy or view summary of this report @ https://www.grandviewresearch.com/industry-analysis/anti-infective-agents-market
Further key findings from the report suggest:
- Antiviral was estimated to be the largest segment with a market
share of 48.8% in 2018 owing to the high price associated with the new
potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
- Antibacterial segment is anticipated to register the fastest CAGR of
4.0% during the forecast period, as antibacterial is the first line of
treatment for a large range of infections. Increased prescription and accessibility
of antibacterial due to their over-the-counter status is anticipated to
further drive the segment
- Development of combination drugs to treat and prevent serious and
life-threatening infections is expected to propel the usage of
anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc.
launched Stribild, a comprehensive treatment regimen inclusive of four
drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil
fumarate) used for the treatment of HIV patients without prior retroviral
treatment record
- Oral route of administration was estimated to be the largest segment
in 2018 owing to new product development and presence of strong product
pipeline
- Hospital pharmacy led the anti-infective agents market in 2018 while
e-commerce is expected to be the fastest growing segment during the
forecast period
- North America was one of the leading regions in terms of revenue in
2018. High prevalence of infectious diseases including hospital-acquired
infections in both, children and adults, and the resultant overuse of
antibiotics coupled with increased accessibility of non-prescription
anti-infectives are the major drivers
- Asia Pacific is one of the fastest growing regional segments owing
to the presence of high, unmet demand for novel drugs, rapid improvements
in healthcare infrastructure coupled with rising awareness among
healthcare professionals and patients
- Some of the major companies operating in this market are Abbott;
Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Merck & Co.,
Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim; and Novartis AG.
- Effective disease management involves a range of long-term
strategies such as new product development, mergers and acquisitions,
co-development, and business expansions. For instance, in 2015, ReViral
received funding of USD 21 million for the development of its RV521 drug
by the Wellcome Trust.
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and fact-based
research across a range of industries, from technology to chemicals, materials
and healthcare.
Contact:
Sherry James
Corporate Sales
Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment